SG10201803535RA - Use of peptides in antibiotic resistance - Google Patents
Use of peptides in antibiotic resistanceInfo
- Publication number
- SG10201803535RA SG10201803535RA SG10201803535RA SG10201803535RA SG10201803535RA SG 10201803535R A SG10201803535R A SG 10201803535RA SG 10201803535R A SG10201803535R A SG 10201803535RA SG 10201803535R A SG10201803535R A SG 10201803535RA SG 10201803535R A SG10201803535R A SG 10201803535RA
- Authority
- SG
- Singapore
- Prior art keywords
- peptides
- antibiotic resistance
- antibiotic
- resistance
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
- A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361898183P | 2013-10-31 | 2013-10-31 | |
US201361905440P | 2013-11-18 | 2013-11-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201803535RA true SG10201803535RA (en) | 2018-05-30 |
Family
ID=52434870
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201803535RA SG10201803535RA (en) | 2013-10-31 | 2014-10-31 | Use of peptides in antibiotic resistance |
SG11201603234WA SG11201603234WA (en) | 2013-10-31 | 2014-10-31 | Use of peptides in antibiotic resistance |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201603234WA SG11201603234WA (en) | 2013-10-31 | 2014-10-31 | Use of peptides in antibiotic resistance |
Country Status (12)
Country | Link |
---|---|
US (1) | US20160303182A1 (en) |
EP (2) | EP3065753B1 (en) |
JP (1) | JP6494616B2 (en) |
KR (1) | KR20160068968A (en) |
CN (1) | CN105828828A (en) |
AU (2) | AU2014343371B2 (en) |
CA (1) | CA2928905A1 (en) |
ES (1) | ES2757563T3 (en) |
HK (1) | HK1222579A1 (en) |
IL (1) | IL245362A0 (en) |
SG (2) | SG10201803535RA (en) |
WO (1) | WO2015063608A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3595698A4 (en) | 2017-03-16 | 2020-12-23 | Microsintesis Inc. | Propiotic molecules for reducing pathogen virulence |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4286988A (en) | 1980-06-30 | 1981-09-01 | The United States Of America As Represented By The Secretary Of The Navy | Copper base antifouling paints with pH control |
US4678512A (en) | 1982-02-12 | 1987-07-07 | Grams Ralph R | Marine coating compositions and method |
GB8511144D0 (en) | 1985-05-02 | 1985-06-12 | Int Paint Plc | Marine anti-fouling paint |
US4865909A (en) | 1987-10-21 | 1989-09-12 | W. L. Gore & Associates, Inc. | Microporous anti-fouling marine coating |
US5143545A (en) | 1991-09-20 | 1992-09-01 | The United States Of America As Represented By The Secretary Of The Navy | Antifouling marine coatings |
US6503881B2 (en) * | 1996-08-21 | 2003-01-07 | Micrologix Biotech Inc. | Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics |
WO2002061087A2 (en) * | 2000-12-19 | 2002-08-08 | Lifespan Biosciences, Inc. | Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides |
EP3670524A1 (en) * | 2008-09-24 | 2020-06-24 | Tel HaShomer Medical Research Infrastructure and Services Ltd. | Peptides and compositions for prevention of cell adhesion and methods of using same |
ES2528133T3 (en) * | 2008-12-29 | 2015-02-04 | Tel Hashomer Medical Research, Infrastructure And Services Ltd. | Peptides and compositions for prevention of cell adhesion, and methods for using them |
US9284351B2 (en) * | 2011-05-31 | 2016-03-15 | Hutchison Biofilm Medical Solutions Ltd. | Dispersion and detachment of cell aggregates |
-
2014
- 2014-10-31 CA CA2928905A patent/CA2928905A1/en not_active Abandoned
- 2014-10-31 US US15/031,658 patent/US20160303182A1/en not_active Abandoned
- 2014-10-31 JP JP2016526353A patent/JP6494616B2/en active Active
- 2014-10-31 SG SG10201803535RA patent/SG10201803535RA/en unknown
- 2014-10-31 AU AU2014343371A patent/AU2014343371B2/en active Active
- 2014-10-31 WO PCT/IB2014/002989 patent/WO2015063608A2/en active Application Filing
- 2014-10-31 CN CN201480066565.8A patent/CN105828828A/en active Pending
- 2014-10-31 ES ES14833181T patent/ES2757563T3/en active Active
- 2014-10-31 EP EP14833181.2A patent/EP3065753B1/en active Active
- 2014-10-31 SG SG11201603234WA patent/SG11201603234WA/en unknown
- 2014-10-31 EP EP19189938.4A patent/EP3632457A1/en not_active Withdrawn
- 2014-10-31 KR KR1020167013517A patent/KR20160068968A/en not_active Application Discontinuation
-
2016
- 2016-05-01 IL IL245362A patent/IL245362A0/en unknown
- 2016-09-14 HK HK16110860.8A patent/HK1222579A1/en unknown
-
2019
- 2019-03-04 AU AU2019201479A patent/AU2019201479A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20160303182A1 (en) | 2016-10-20 |
CA2928905A1 (en) | 2015-05-07 |
WO2015063608A3 (en) | 2015-08-06 |
SG11201603234WA (en) | 2016-05-30 |
EP3065753B1 (en) | 2019-09-11 |
AU2014343371B2 (en) | 2019-03-14 |
AU2019201479A1 (en) | 2019-03-28 |
JP2016536310A (en) | 2016-11-24 |
JP6494616B2 (en) | 2019-04-03 |
WO2015063608A9 (en) | 2015-12-03 |
HK1222579A1 (en) | 2017-07-07 |
AU2014343371A1 (en) | 2016-06-16 |
EP3632457A1 (en) | 2020-04-08 |
WO2015063608A2 (en) | 2015-05-07 |
CN105828828A (en) | 2016-08-03 |
KR20160068968A (en) | 2016-06-15 |
EP3065753A2 (en) | 2016-09-14 |
ES2757563T3 (en) | 2020-04-29 |
IL245362A0 (en) | 2016-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL276106A (en) | Anti-garp protein and uses thereof | |
HK1248138A1 (en) | Imidazopyridine compounds and uses thereof | |
HK1223975A1 (en) | Nanobubble-containing composition and use thereof | |
ZA201505705B (en) | Phi-4 polypeptides and methods for their use | |
ZA201505966B (en) | Peptides and compositions | |
GB201317286D0 (en) | Composition and Use | |
HK1214333A1 (en) | Bracket and use | |
GB201321693D0 (en) | Composition and uses thereof | |
PT3058936T (en) | Peptide composition and uses thereof | |
EP2910131A4 (en) | Anti-fatigue composition and use thereof | |
GB201307989D0 (en) | Novel combinations and use | |
HK1211596A1 (en) | Peptide | |
GB201320992D0 (en) | Complex and uses thereof | |
HK1211595A1 (en) | Peptide | |
HK1222579A1 (en) | Use of peptides in antibiotic resistance | |
ZA201601880B (en) | Hetero-transglycosylase and uses thereof | |
GB201418840D0 (en) | In german | |
EP3006564A4 (en) | New peptide and application thereof | |
GB201301640D0 (en) | Methods and peptides | |
GB201322467D0 (en) | Composition and use | |
GB201301922D0 (en) | Resistance | |
GB201311011D0 (en) | Mavrik all in one | |
GB201301022D0 (en) | Composition and uses thereof |